Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

94 results
Display

Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist

Lee I, Kang ES

According to the American Diabetes Association (ADA) and the European Association for the Study of Diabetes guideline for treatment of diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) is recommended in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Oral Hypoglycemic Agents for Patients with Type 2 Diabetes Mellitus

Ko SH

For patients with newly diagnosed type 2 diabetes mellitus (T2DM), lifestyle modifications including medical nutrition therapy, weight control, physical activity, smoking cessation, and avoidance of alcohol abuse should be initiated....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans

Sargeant J, Henson J, King JA, Yates T, Khunti K, Davies MJ

Weight loss is an important goal in the management of several chronic conditions, including type 2 diabetes mellitus, and pharmacological therapies that aid weight loss are appealing. Glucagon-like peptide-1 receptor...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Downregulation of IL-18 Expression in the Gut by Metformin-induced Gut Microbiota Modulation

Lee H, Kim J, An J, Lee S, Choi D, Kong H, Song Y, Park IH, Lee CK, Kim K

IL-18 is a crucial pro-inflammatory cytokine that mediates chronic intestinal inflammation. Metformin, an anti-diabetic drug, was reported to have ameliorative effects on inflammatory bowel disease. Recently, the mechanism of action...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Factors Related to Blood Intact Incretin Levels in Patients with Type 2 Diabetes Mellitus

Yoo S, Yang EJ, Koh G

BACKGROUND: We performed this study to identify factors related to intact incretin levels in patients with type 2 diabetes mellitus (T2DM). METHODS: We cross-sectionally analyzed 336 patients with T2DM. Intact glucagon-like...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials

Kang YM, Cho YK, Lee J, Lee SE, Lee WJ, Park JY, Kim YJ, Jung CH, Nauck MA

BACKGROUND: Based on reported results of three large cardiovascular outcome trials (CVOTs) of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), we aimed to investigate the overall effect of GLP-1 RAs...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea

Kim MK, Ko SH, Kim BY, Kang ES, Noh J, Kim SK, Park SO, Hur KY, Chon S, Moon MK, Kim NH, Kim SY, Rhee SY, Lee KW, Kim JH, Rhee EJ, Chun S, Yu SH, Kim DJ, Kwon HS, Park KS, Committee of Clinical Practice Guidelines, Korean Diabetes Association

The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 6th Clinical Practice Guidelines in 2019. Targets of glycemic, blood pressure, and lipid control in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Saxenda® Frenzy: Opinions of an Endocrine and Metabolism Specialist

Kim S

Globally, the problem of obesity is increasing, and the prevalence of obesity in Korea is also rising rapidly. Obesity is a risk factor for cardiometabolic diseases including type 2 diabetes...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes

Kim GS, Park JH, Won JC

The prevalence of type 2 diabetes mellitus (T2DM), which is associated with cardiovascular morbidity and mortality, is increasing worldwide. Although there have been advances in diabetes treatments that reduce microvascular...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke

Ahn CH, Lim S

Patients with hyperglycemia are at a high risk of cardio- and cerebrovascular diseases. Diabetes patients also have poor outcomes after cerebrovascular disease development. Several classes of drugs are used for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists

Jung CH, Mok JO

The only known, effective intervention for non-alcoholic fatty liver disease (NAFLD) is weight loss, and there is no approved pharmacotherapy. Recently, new hypoglycemic agents, such as sodium-glucose cotransporter 2 (SGLT2)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Management of Hyperglycemia in Type 2 Diabetes: A Summary of New Consensus Report from the American Diabetes Association and the European Association for the Study of Diabetes in 2018

Kim JM, Kim SS

In 2018, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) published a consensus recommendation on management of hyperglycemia. This consensus report emphasized the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Premeal Consumption of a Protein-Enriched, Dietary Fiber-Fortified Bar Decreases Total Energy Intake in Healthy Individuals

Ahn CH, Bae JH, Cho YM

BACKGROUND: A premeal load of protein can increase satiety and reduce energy intake. Dietary fiber also conveys metabolic benefits by modulating energy intake. We made a protein-enriched, dietary fiber-fortified bar...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Latent Autoimmune Diabetes in Adults: Current Status and New Horizons

Pozzilli P, Pieralice

Autoimmune diabetes is a heterogeneous disease which can arise at any age. Subjects with adult-onset autoimmune diabetes who do not necessitate insulin-therapy for at least 6 months after diagnosis are...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cardiovascular Outcome Trials of Incretin Therapy (Dipeptidyl Peptidase-4 Inhibitors/Glucagon-Like Peptide-1 Receptor Agonist)

Jeong IK

In 2008, the United States Food and Drug Administration issued guidance which mandated long-term cardiovascular outcome trials (CVOTs) to assess the safety of new antidiabetic drugs for type 2 diabetes....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
YH18968, a Novel 1,2,4-Triazolone G-Protein Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes Mellitus

Han T, Lee BM, Park YH, Lee DH, Choi HH, Lee T, Kim H

G protein-coupled receptor 119 (GPR119) is expressed in the pancreas and gastrointestinal tract, and its activation promotes insulin secretion in the beta cells of the pancreatic islets as well as...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Response: Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-Related Factors in Health Screen Examinees (J Obes Metab Syndr 2017;26:188-96)

Lee JY, Jang BK, Song MK, Kim HS, Kim MK

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Letter: Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-Related Factors in Health Screen Examinees (J Obes Metab Syndr 2017;26:188-96)

Koh G

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association

Kim HJ

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Crosstalk between FXR and TGR5 controls glucagon-like peptide 1 secretion to maintain glycemic homeostasis

Kim H, Fang S

Though bile acids have been well known as digestive juice, recent studies have demonstrated that bile acids bind to their endogenous receptors, including Farnesoid X receptor (FXR) and G protein-coupled...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr